<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667639</url>
  </required_header>
  <id_info>
    <org_study_id>RPH104FIH01</org_study_id>
    <nct_id>NCT02667639</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRPHARM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MonitorCRO</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>TRPHARM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first in human study is to evaluate the safety and tolerability of
      RPH-104 in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RPH-104 is a macromolecular compound with a molecular weight of 152.715 kilodalton (Data on
      file) and is capable of binding human interleukin-1 beta (IL-1β). It has also been shown in
      vitro to be a highly potent inhibitor of IL-1β signalling pathway, with low picomolar
      inhibitor activity. In this First in Human study, RPH-104 will be evaluated primarily for its
      safety and tolerability. In a phase I study conducted with health volunteers, a similar
      monoclonal antibody, canakinumab, was investigated in terms of pharmacokinetics and
      pharmacodynamics besides efficacy and safety. Similarly, this aimed to investigate effects of
      RPH-104 on selected pharmacodynamic parameters, including Anti-Drug Antibodies (ADA) along
      with obtaining first human data on pharmacokinetics of RPH-104 in humans will be investigated
      in the same study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Until 60 days after administration</time_frame>
    <description>Number of participants with study drug related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Until 60 days after administration</time_frame>
    <description>Number of Participants with Study Drug Related Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>Until 30 days after administration</time_frame>
    <description>Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Until 30 days after administration</time_frame>
    <description>Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>Until 30 days after administration</time_frame>
    <description>Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Until 30 days after administration</time_frame>
    <description>Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Until 30 days after administration</time_frame>
    <description>Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Area Under the Curve (AUC)</measure>
    <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
    <description>Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Time to Maximum Concentration (Tmax)</measure>
    <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
    <description>Median Tmax. Definition of Tmax is time at which Cmax occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Elimination Half-life (t1/2)</measure>
    <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
    <description>Mean t½. Definition of t½ is terminal elimination half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPH-104 - Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
    <description>Mean Cmax. Highest concentration determined in the measuring interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single 0.9% sodium chloride injection will be administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RPH-104</intervention_name>
    <description>Anti-IL-1 Mab</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium chloride Sterile Injection 0.9% w/v</intervention_name>
    <description>Sterile saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects.

          -  Male or female subjects between 18 and 35 years old (inclusive).

          -  Subject who has normal body weight as determined by a body mass index (BMI) of between
             18 kg/m² and 30 kg/m² (inclusive) and within a body weight of ≥50kg and ≤120kg.

        Exclusion Criteria:

          -  Subject who has a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrinological, dermatological, neurological, psychiatric, and
             hematological or immunological disorder(s), and/or any condition that could constitute
             a potential safety risk factor or could alter the absorption, distribution, metabolism
             or elimination of the study drugs.

          -  Subject who has positive immunoglobulin-M (IgM) antibodies against Epstein-Barr virus
             (EBV)-viral capsid antigen (VCA) (IgM-anti-EBV-VCA) and Cytomegalovirus (CMV).

          -  Subject who has a positive Quantiferon TB-Gold (TB) test

          -  Subject who is positive to Human Immunodeficiency Virus-1/2 antibody (HIV-1/2Ab).

          -  Subject who has serum hepatitis, or is a carrier of the Hepatitis B surface antigen
             (HBsAg), or is Hepatitis C virus antibody (HCV-Ab) positive.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sibel Goksel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ARGEFAR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ARGEFAR</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <results_first_submitted>April 12, 2018</results_first_submitted>
  <results_first_submitted_qc>September 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2019</results_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>RPH-104</keyword>
  <keyword>RPH104</keyword>
  <keyword>Anti-IL1 beta</keyword>
  <keyword>Anti-IL1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02667639/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) is administered subcutaneously.
RPH-104</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A single 0.9% sodium chloride injection is administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects receiving the study medication will be included into the safety evaluation. Subjects who completed the study according to the protocol (per protocol population) will be included into the statistical evaluation. Subject data of drop-out volunteers or volunteers who were not eligible for the study will not be included into statistics.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) is administered subcutaneously.
RPH-104</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A single 0.9% sodium chloride injection is administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Physical examination, ID check and data entry to study specific Case Report Form.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Physical examination and data entry to study specific Case Report Form.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Data entry to study specific Case Report Form.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Number of participants with study drug related adverse events</description>
        <time_frame>Until 60 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) is administered subcutaneously.
RPH-104</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection is administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of participants with study drug related adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>Number of Participants with Study Drug Related Serious Adverse Events</description>
        <time_frame>Until 60 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) is administered subcutaneously.
RPH-104</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection is administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Number of Participants with Study Drug Related Serious Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Rate</title>
        <description>Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.</description>
        <time_frame>Until 30 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate</title>
          <description>Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <description>Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg</description>
        <time_frame>Until 30 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oxygen Saturation</title>
        <description>Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.</description>
        <time_frame>Until 30 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Saturation</title>
          <description>Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Temperature</title>
        <description>Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).</description>
        <time_frame>Until 30 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Tests</title>
        <description>Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.</description>
        <time_frame>Until 30 days after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Tests</title>
          <description>Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RPH-104 - Area Under the Curve (AUC)</title>
        <description>Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)</description>
        <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>RPH-104 - Area Under the Curve (AUC)</title>
          <description>Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74500" spread="24700"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430000" spread="95700"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661000" spread="158000"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1610000" spread="317000"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>160 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3390000" spread="1450000"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RPH-104 - Time to Maximum Concentration (Tmax)</title>
        <description>Median Tmax. Definition of Tmax is time at which Cmax occurs.</description>
        <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>RPH-104 - Time to Maximum Concentration (Tmax)</title>
          <description>Median Tmax. Definition of Tmax is time at which Cmax occurs.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94.4" upper_limit="192"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="48" upper_limit="96.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="96.0" upper_limit="192"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="72.0" upper_limit="120"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>160 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="72.0" upper_limit="120"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RPH-104 - Elimination Half-life (t1/2)</title>
        <description>Mean t½. Definition of t½ is terminal elimination half-life.</description>
        <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>RPH-104 - Elimination Half-life (t1/2)</title>
          <description>Mean t½. Definition of t½ is terminal elimination half-life.</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" spread="9.50"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" spread="6.08"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="43.1"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235" spread="22.8"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>160 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" spread="40.4"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RPH-104 - Maximum Plasma Concentration (Cmax)</title>
        <description>Mean Cmax. Highest concentration determined in the measuring interval.</description>
        <time_frame>Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.
RPH-104: Anti-IL-1 Mab</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single 0.9% sodium chloride injection will be administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v: Sterile saline solution</description>
          </group>
        </group_list>
        <measure>
          <title>RPH-104 - Maximum Plasma Concentration (Cmax)</title>
          <description>Mean Cmax. Highest concentration determined in the measuring interval.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" spread="89.1"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1280" spread="402"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1650" spread="257"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5120" spread="1410"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>160 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10300" spread="4470"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) is administered subcutaneously.
RPH-104</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A single 0.9% sodium chloride injection is administered subcutaneously.
Sodium chloride Sterile Injection 0.9% w/v</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Murat Özdemir</name_or_title>
      <organization>Monitor CRO</organization>
      <phone>902122341260</phone>
      <email>murato@monitorcro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

